Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Outcomes Study of Omarigliptin in Type 2 Diabetes Mellitus
2012-002414-39Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Omarigliptin 25 mg once weekly with Placebo (2 arms). Primary endpoints: Change from baseline in HbA1c and Change from baseline in fasting plasma glucose. Started Sep 2012; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002414-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002414-39.